PARD — Poniard Pharmaceuticals Share Price
Last trade - 00:00- $0.00m
- -$0.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -326.53% | ||
| Return on Equity | -212.95% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2006 | 2007 | 2008 | 2009 | 2010 | 2011E | 2012E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of oncology products to impact the lives of people with cancer. It develops picoplatin, a platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. The Company has offices in San Francisco, California; and Seattle, Washington in United States.
Directors
- Ronald Martell CHM (54)
- Robert Basso IND (67)
- Frederick Craves IND (75)
- Carl Goldfischer IND (62)
- Robert Littauer IND (56)
- David Stevens IND (72)
- Last Annual
- December 31st, 2010
- Last Interim
- September 30th, 2011
- Incorporated
- May 11th, 1984
- Public Since
- December 30th, 2011
- No. of Shareholders
- 564
- No. of Employees
- 20
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,499,232
- Address
- 750 Battery Street, Suite 330, SAN FRANCISCO, 94111
- Web
- Phone
- +1 2062862501
- Auditors
- Ernst & Young LLP
Similar to PARD
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 21:41 UTC, shares in Poniard Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Poniard Pharmaceuticals last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Poniard Pharmaceuticals share price has underperformed the S&P500 Index by -13.47% over the past year.
There is no consensus recommendation for this security.
Find out morePoniard Pharmaceuticals does not currently pay a dividend.
Poniard Pharmaceuticals does not currently pay a dividend.
Poniard Pharmaceuticals does not currently pay a dividend.
To buy shares in Poniard Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Poniard Pharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for Poniard Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PARD
Based on an overall assessment of its quality, value and momentum Poniard Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Poniard Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -99.02%.
As of the last closing price of $0.00, shares in Poniard Pharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Poniard Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Poniard Pharmaceuticals' management team is headed by:
- Ronald Martell - CHM
- Robert Basso - IND
- Frederick Craves - IND
- Carl Goldfischer - IND
- Robert Littauer - IND
- David Stevens - IND